(2- fluorobenzyl)- (2- methyl- 2- phenyl- 2H- chromen- 6- yl- amine)

a 5-lipoxygenase inhibitor that decreases angiogenesis via inhibition of HIF-1alpha; structure in first source

Also Known As:

(2-fluorobenzyl)-(2-methyl-2-phenethyl-2H-chromen-6-yl)-amine; KRH 102140; KRH-102140; KRH102140

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Osteosarcoma (Osteogenic Sarcoma) 03/01/2011 - "KRH102140 more efficiently suppressed HIF-1α than KRH102053 in human osteosarcoma cells under hypoxia. "
2.	Inflammation (Inflammations) 01/01/2011 - "Oral administration of KRH-102140 (10-100 mg/kg) reduced ear edema, myeloperoxidase activity and LTB(4) production in murine inflammation models. "
3.	Edema (Dropsy) 01/01/2011 - "Oral administration of KRH-102140 (10-100 mg/kg) reduced ear edema, myeloperoxidase activity and LTB(4) production in murine inflammation models. "
4.	Hypoxia (Hypoxemia) 03/01/2011 - "KRH102140 more efficiently suppressed HIF-1α than KRH102053 in human osteosarcoma cells under hypoxia. "

1.	Peroxidase (Myeloperoxidase)
2.	2-amino-4-methylsulfanylbutyric acid 4- methoxy- 6- (4- methoxybenzylamino)- 2,2- dimethylchroman- 3- yl ester

1.	Oral Administration